The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women.
Evidence based treatment of cardiovascular risk factors on outcome in women is still inconclusive given the very large numbers needed to achieve a significant difference in cardiovascular event. Although numerous studies of the effect of hormone replacement therapy (HRT) on risk factors have suggested benefit, the only data from a randomised control trial of HRT in secondary prevention was neutral. Coronary disease-primary prevention: (a) Statins: Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEX CAPS). The only randomised controlled trial (RCT) to include women. There were fewer coronary heart disease (CHD) events in women but no difference in mortality. (b) HRT: no completed RCT-the results from Womens Health Initiative (WHI) and Women Intervention Study of Long Duration of Oestrogen in the Menopause (WISDOM) are awaited, the former likely to complete in 2004. There are numerous reports of positive observational epidemiological studies for HRT. There is little evidence for statin use in women who will probably not qualify for treatment on global CHD risk assessment, familial hypercholesterolemia and type 2 diabetes excepted. HRT is, therefore, not only appropriate for its multiple effects on lipoproteins, vascular function and insulin sensitivity but also for prevention of osteoporosis. Coronary disease-
(a) Statins: the major measurable effect of these drugs is to reduce total and LDL cholesterol. In RCT trials, the Scandanavian Simvastatin Survival Study (4S), the Cholesterol and Recurrent Event (CARE) and Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID), approximately 20% of subjects were female, in whom CHD events, but not CHD or total mortality were reduced. (b) HRT: there is data available from a single RCT of continuous combined premarin and medroxyprogesterone acetate (MPA) against placebo, The Heart Estrogen Replacement Study (HERS). A study of 2763 women and mean duration of 4.1 years. This study was neutral, with no reduction in CHD events or mortality. There were more events in the first year, and fewer in years 3-5. Other studies of HRT have been observational and positive for HRT. The effects of treatment on lipoproteins with statins, HRT and combination of statin and HRT have been investigated. In secondary prevention for hyperlipidemic women to achieve cholesterol <5, low density lipoprotein (LDL)<3 mmol/l statins will be first choice, possibly with HRT additionally for its other benefits on cardiovascular risk factors.
Seed
Mary
M
Department of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College School of Medicine, Charing Cross Hospital Campus, London, UK. m.seed@ic.ac.uk
D003327:Coronary Disease / Q000401:mortality / Q000517:prevention & control*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000517:prevention & control*; D050356:Lipid Metabolism; D008148:Lovastatin / Q000627:therapeutic use*; D017698:Postmenopause; D011322:Primary Prevention; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008148:Lovastatin